WallStSmart

Merck & Company Inc (MRK)vsVSee Health, Inc. (VSEE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 454825% more annual revenue ($65.77B vs $14.46M). MRK leads profitability with a 13.6% profit margin vs -92.4%. MRK earns a higher WallStSmart Score of 50/100 (D+).

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.30

VSEE

Avoid

28

out of 100

Grade: F

Growth: 5.3Profit: 2.0Value: 5.0Quality: 5.0
Piotroski: 4/9Altman Z: -6.47
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-49.3%)

Margin of Safety

-49.3%

Fair Value

$80.88

Current Price

$120.79

$39.91 premium

UndervaluedFair: $80.88Overvalued

Intrinsic value data unavailable for VSEE.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$285.64B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

VSEE1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.269/10

Conservative balance sheet, low leverage

Areas to Watch

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

VSEE4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$7.13M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-258.8%2/10

ROE of -258.8% — below average capital efficiency

Revenue GrowthGrowth
-4.9%2/10

Revenue declined 4.9%

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : VSEE

The strongest argument for VSEE centers on Debt/Equity.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Bear Case : VSEE

The primary concerns for VSEE are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

MRK profiles as a value stock while VSEE is a turnaround play — different risk/reward profiles.

VSEE carries more volatility with a beta of 0.42 — expect wider price swings.

MRK is growing revenue faster at 4.9% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (50/100 vs 28/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

VSee Health, Inc.

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

VSee Health, Inc. is a pioneering leader in the telehealth industry, delivering secure and intuitive video communication solutions specifically designed for healthcare professionals and patients. The company's versatile platform features essential functionalities, including remote patient monitoring, asynchronous messaging, and robust electronic medical record (EMR) interoperability, aimed at improving healthcare delivery efficiency and quality across diverse medical specialties. By prioritizing patient engagement and accessibility, VSee serves a broad international client base, strategically positioning itself to leverage the increasing demand for virtual care in the transforming healthcare landscape. With a focus on innovation and customer success, VSee Health is well-equipped for substantial growth as digital healthcare solutions become increasingly critical.

Visit Website →

Want to dig deeper into these stocks?